Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity

ROCKVILLE, Md. and SUZHOU, China, Jan. 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. , a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality...

Related Keywords

China ,Suzhou ,Jiangsu ,Peking ,Beijing ,Hong Kong ,Taiwan ,Macau ,United States ,Chinese ,Linong Ji ,Innovent Biologics ,Adimab Incyte ,Eli Lilly ,Institute For Health Metrics ,Incyte Corporation ,Prnewswire Innovent Biologics Inc ,Clinical Development At Innovent ,Company Lilly ,Global Health Data Exchange ,University People Hospital ,Md Anderson Cancer Center ,Innovent Rd Code ,Peking University People ,Lei Qian ,Vice President ,Clinical Development ,Sintilimab Injection ,Bevacizumab Injection ,Adalimumab Injection ,Rituximab Injection ,Pemigatinib Oral Inhibitor ,Ramucirumab Injection ,Selpercatinib Capsules ,Autoleucel Injection ,Tafolecimab Injection ,Cancer Center ,Mainland China ,Lancet Diabetes Endocrinol ,Health Metrics ,Global Health Data ,Markets ,